SCP
HZNP

Syntal Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Syntal Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-23,741
Closed -$1.84M – 135
2020
Q3 		$1.84M Buy
23,741
+35
+0.1% +$2.41K 0.83% 22
2020
Q2 		$1.32M Buy
+23,706
New +$1.01M 0.62% 51

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Syntal Capital Partners's HZNP Position: Q4 2020 in Review

Syntal Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 23,741 shares — an estimated $1.84M sold.

Syntal Capital Partners first reported a position in HZNP in Q2 2020 and held it in 2 quarters. The position peaked at $1.84M in Q3 2020. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

  • Syntal Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
  • Syntal Capital Partners sold 23,741 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $1.84M.
  • Syntal Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 2 quarters.
  • Syntal Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.84M in Q3 2020.
  • 497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Syntal Capital Partners's 13F filing for Q4 2020, filed 11 Feb 2021.